777-28-6 Usage
General Description
3-(2,4-difluorophenoxy)propanoic acid, also known as fenofibric acid, is a chemical compound with a molecular formula C12H9F2O3. It is a derivative of fibric acid and is commonly used as a medication to lower cholesterol and triglyceride levels in the blood. 3-(2,4-difluorophenoxy)propanoic acid works by increasing the enzyme activity involved in the breakdown of fatty acids, thereby reducing the production of triglycerides and cholesterol. It is typically administered orally in the form of tablets or capsules and is often used in conjunction with diet and exercise to manage hyperlipidemia and other lipid disorders. While generally well-tolerated, fenofibric acid may cause side effects such as stomach pain, nausea, and muscle pain, and should be used with caution in individuals with liver or kidney disease.
Check Digit Verification of cas no
The CAS Registry Mumber 777-28-6 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 7,7 and 7 respectively; the second part has 2 digits, 2 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 777-28:
(5*7)+(4*7)+(3*7)+(2*2)+(1*8)=96
96 % 10 = 6
So 777-28-6 is a valid CAS Registry Number.
InChI:InChI=1/C9H8F2O3/c10-6-1-2-8(7(11)5-6)14-4-3-9(12)13/h1-2,5H,3-4H2,(H,12,13)
777-28-6Relevant articles and documents
Synthesis, determination of absolute configuration, and biological evaluation of spiro-fused thiadiazoline inhibitors of kinesin spindle protein (KSP)
Angeles, Angie R.,Yang, Liping,Dai, Chaoyang,Brunskill, Andrew,Basso, Andrea D.,Siddiqui, M. Arshad
supporting information; experimental part, p. 6236 - 6239 (2011/01/12)
A facile and highly convergent synthesis of biologically active spiro-fused thiadiazoline KSP inhibitors is reported. The highlights of the synthesis include the Michael reaction and cyclization of thiosemicarbazone to 1,3,4-thiadiazoline. This chemistry lends itself to the preparation of (+)-2, a potent and orally bioavailable anti-cancer agent, and to the development of a structure-activity relationship program.
